Generic Drug Development

Sterne Kessler’s generic drug team combines deep understanding of small molecule drug innovators’ IP with an exceptional ANDA litigation capability.

Sterne Kessler’s generic drug team helps clients navigate the interface between patent law and the FDA approval process. Our work includes patent validity and infringement analyses; exclusivity strategies; ANDA applications and litigation; patent term extension applications; orange book listing strategies; and appeals before the Federal Circuit.

Many decades of experience helping pharmaceutical innovators protect and defend the IP surrounding their FDA-approved drugs provides Sterne Kessler with a unique and advantageous perspective on potential avenues for developing and launching generic equivalents. We understand lifecycle oriented patent portfolios, patent term extensions,and potential weaknesses in innovators’ portfolios.

In Hatch-Waxman and ANDA matters, we have assembled a deep bench of experienced litigators, technical experts and attorneys and agents with extensive experience representing both brand and generic pharmaceutical companies in blockbuster ANDA matters. More than 70 of our professionals have experience in ANDA challenges.

Our body of ANDA work comprises more than 75 Paragraph IV filings and over 600 opinions. Sterne Kessler was the first firm to file an inter partes review petition as part of an ANDA dispute. Our attorneys draw on their experience from 400+ reexaminations, 50+ interference proceedings and 575+ inter partes reviews.

Related Resources

Speaking Engagement

20th Paragraph IV Disputes Conference

April 25, 2024 10:30 AM - 11:30 AM PST

Press Release

Sterne Kessler Promotes Eight Attorneys to Counsel

Sterne, Kessler, Goldstein & Fox March 25, 2024

In the News

Petition Watch: Patent Obviousness, ADA Trials, Spoofing

Law360 January 25, 2024

Webinar Recordings & Materials

Federal Circuit IP Appeals: Summaries of Key 2023 Decisions

January 23, 2024

In the News

Teva Defeats Infringement Claims on Endocrine Drug

New Jersey Law Journal January 3, 2024

Firm Announcements

Sterne Kessler Secures Non-Infringement Win for Teva Pharmaceuticals

Sterne, Kessler, Goldstein & Fox January 3, 2024

Press Release

Sterne Kessler Presented With Two Top Honors at 2023 LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox September 8, 2023

Speaking Engagement

FDA and PTO Panel

July 1, 2023 9:45 AM - 10:45 AM PST

Speaking Engagement

Preparing for Biosimilar Carve Outs: Will Skinny Labelling Work for Biosimilars?

June 27, 2023 4:15 PM - 5:15 PM PST

Speaking Engagement

Roundtable Discussion Group: Patentability of Diagnostic Techniques

May 4, 2023 11:45 AM - 1:20 PM PST

Speaking Engagement

Chairman’s Opening Address and Closing Remarks

May 3, 2023 9:00 AM - 5:00 PM PST

Speaking Engagement

2023 Focus on Pharma

April 14, 2023 8:30 AM - 6:00 PM PST

Webinar

Patent Term Extensions for Pharma Products in Europe and the USA

March 15, 2023 11:00 AM - 12:00 PM PST

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox January 30, 2023

MarkIt to Market®

MarkIt to Market® – January 2023

January 30, 2023

In the News

Teva, Apotex Win Ax of Patents in Sleep Drug Suit

Law360 December 13, 2022

Speaking Engagement

Patents in the Cross-Hairs of the Affordable Drug Conversation

December 5, 2022 9:30 AM - 10:30 AM PST

Speaking Engagement

Opening Address and Closing Remarks

November 1, 2022 8:30 AM - 6:25 PM PST

Press Release

Sterne Kessler Director Eldora L. Ellison Appointed to Advisory Council for the CAFC

Sterne, Kessler, Goldstein & Fox September 30, 2022

In the News

Gilead Settles HIV Drugs Patent Suit on Eve of Bench Trial

Law360 September 12, 2022

In the News

New Trustees to Join Cornell Board

Cornell Chronicle June 2, 2022

Speaking Engagement

Chairman’s Opening Address and Closing Remarks

May 11, 2022 9:00 AM - 4:45 PM PST

In the News

Almirall Loses Appeal on Acne Treatment Patent at Fed. Cir.

Bloomberg Law March 14, 2022

In the News

Fed. Circ. Affirms PTAB’s Ax of Acne Drug Patent

Law360 March 14, 2022

In the News

Litigator of the Week Runners-Up and Shout Outs

Law.com February 18, 2022

In the News

Federal Circuit Tosses Naloxone Patents

Law Street Media February 11, 2022

In the News

Teva Win Invalidating Narcan Patents Upheld by Federal Circuit

Bloomberg Law February 10, 2022

In the News

Split Fed. Circ. Won’t Restore 4 Narcan Patents

Law360 February 10, 2022

In the News

USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing

Pink Sheet September 23, 2021

In the News

Conflict of Interest: How Five Firms Make Close Calls

Managing IP August 6, 2021

In the News

Adapt Faces Tough Questions in Bid to Revive Narcan Patents

Bloomberg Law August 2, 2021

In the News

IP Forecast: Fed. Circ. To Mull Narcan Patents

Law360 July 29, 2021

Bylined Articles

Amneal Pharm. LLC v. Almirall, LLC, 960 F.3d 1368 (Fed. Cir. 2020)

Sterne, Kessler, Goldstein & Fox January 26, 2021

Webinar

A Tool Box for Success in Early Stage Pharma Medical Initiatives

January 12, 2021 8:00 AM - 10:00 AM PST

Press Release

Sterne Kessler Named Among 2021 “Best Law Firms” by Best Lawyers

Sterne, Kessler, Goldstein & Fox November 6, 2020

In the News

Justices Skip Case Horizon Said Puts 32K Patents At Risk

Law360 November 3, 2020

Webinar

Drug Development Pathway Series: Intellectual Property Workshop

October 28, 2020 4:00 PM - 5:00 PM PST

Press Release

Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020

Press Release

Sterne, Kessler, Goldstein & Fox Wins Two 2020 LMG Life Sciences Americas Awards

Sterne, Kessler, Goldstein & Fox P.L.L.C. September 24, 2020

Client Alert

IP Hot Topic: Patent Prosecution Tool Kit

July 7, 2020

Reports

Patent Prosecution Tool Kit

Sterne, Kessler, Goldstein & Fox July 7, 2020

Bylined Articles

Patenting the Product Label

Sterne, Kessler, Goldstein & Fox July 7, 2020

Bylined Articles

Implications of the BPCIA on the IP Strategies of Brand Companies and Biosimilar Developers

Sterne, Kessler, Goldstein & Fox July 7, 2020

Bylined Articles

Patent Term Extension

Sterne, Kessler, Goldstein & Fox July 7, 2020

Bylined Articles

Biopharma Patentees Must Navigate Inherent Obviousness

Law360 June 23, 2020

In the News

Teva Invalidates Opiant Patents In Narcan Suit

Law360 June 5, 2020

In the News

Federal Circuit Ruling Could Put Certain Drug Patents At Risk

Bloomberg Law December 31, 2019

In the News

Teva Gets PTAB To Review Cushing’s Syndrome Drug Patent

Law360 November 21, 2019

Presentations

2019 Focus on Pharma Conference (presentations)

October 25, 2019

In the News

PTAB Cuts Down Two More Allergan Restasis Patents

Law360 September 30, 2019

Press Release

Director Eldora L. Ellison, Ph.D. Receives Top Honor at 2019 LMG Life Sciences Awards

Sterne, Kessler, Goldstein & Fox P.L.L.C September 23, 2019

Bylined Articles

Proposed BPCIA reforms: More music, same dance

Managing Intellectual Property May 16, 2019

Speaking Engagement

13th Annual Paragraph IV Disputes

April 29, 2019

In the News

Fed. Circ. Won’t Revisit Restasis Patent Ruling

Law360 April 6, 2019

In the News

Fed. Circ. Won’t Revisit Restasis Patent Ruling

Law360 March 6, 2019

Bylined Articles

Federal Circuit Issues Further Guidance On AIA Proceeding Standing To Appeal

Sterne, Kessler, Goldstein & Fox P.L.L.C February 22, 2019

Speaking Engagement

Access! 2019 – AAM Annual Meeting

February 4, 2019

Bylined Articles

What Cannabis Patent Applicants Can Learn From Biopharma

Law360 January 17, 2019

In the News

J&J Tells Fed. Circ. Judge Was Wrong To Nix Zytiga Patent

Law360 December 4, 2018

In the News

Allergan, Generic Cos. Battle Over Restasis Launch Plans

Law360 October 31, 2018

Speaking Engagement

Microbiome R&D and Business Collaboration Forum: USA

October 29, 2018 12:00 AM - 11:59 PM PST

In the News

Fed. Circ. Rejects Bid For PTAB Tribal Immunity Rehearing

Law360 October 22, 2018

Press Release

Sterne Kessler Recognized By LMG Life Sciences Among The Top IP Firms and Attorneys

Sterne, Kessler, Goldstein & Fox September 25, 2018

In the News

No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears

Law360 September 19, 2018

In the News

Generics Cos. Urge Fed. Circ. To Upend Depomed Patent Win

Law360 September 4, 2018

In the News

Biologic Fights Drive PTAB Drug Challenges To Record High

Law360 February 8, 2018

Global Patent Prosecution

Global Patent Prosecution Newsletter – December 2017

December 18, 2017

Bylined Articles

Bolar Exemptions in North America

Sterne, Kessler, Goldstein & Fox December 18, 2017

Bylined Articles

Bolar Exemption in Europe and Asia

Sterne, Kessler, Goldstein & Fox December 18, 2017

Bylined Articles

Worldwide Bolar-type Provisions*

Sterne, Kessler, Goldstein & Fox December 18, 2017

In the News

To Use A Generic Drug Application, Or Not, That’s The Question

Bloomberg Law - Pharmaceutical Law & Industry Report October 20, 2017

In the News

Judge Hacks Away At Allergan’s Restasis Patents

Law360 October 18, 2017

Global Patent Prosecution

Global Patent Prosecution Newsletter – July 2017

July 17, 2017

Bylined Articles

Biosimilar Uptake and Patent Litigation in Japan

Sterne, Kessler, Goldstein & Fox July 17, 2017

Publication

Approved Biosimilar Products Around the World

Sterne, Kessler, Goldstein & Fox July 17, 2017

Bylined Articles

Divided Infringement After Eli Lilly V. Teva

Law360 April 18, 2017

Bylined Articles

Top 5 PTAB Tips for Big Pharma

New Jersey Law Journal April 3, 2017